Clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can help align domestic and foreign experts and teams to provide accurate diagnosis and treatment plans. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immunodeficiency disorders that were previously difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to the changes in the course of treatment.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of lupus erythematosus (LVI). The platform serves the China International Medical Service System, a team of internationally authorized experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.